{"text_format":"3","workbook":"xls","n_sheets":1,"sheets":["Table 1"],"not_rendered":{"external_links":1,"defined_names":1,"comments":6},"read":"whole","date_system":"1904","formulas":"cached_only"}

{"sheet":"Table 1","index":0,"n_rows":72,"n_cols":13,"rows_kept":72,"merged":[[0,0,0,3]],"flags":["formulas_cached_only"]}
["Table 1. Characteristics of 60 EGPA patients with treated by mepolizumab"]
[null," CS+IS+Mepolizumab group"," CS+Mepolizumab group"]
[null,"N = 40","N = 20","P-value"]
["Age at study admission (years), mean ± 1 SD","58.4 ± 13.8","62.0 ± 12.4",0.32]
["Sex (M/F)","13/27","9/11","0.90"]
["Age at asthma onset (years), mean ± SD","34.4 ± 16.4","46.4 ± 19.6","0.015"]
["Age at EGPA diagnosis (years), mean ± SD","45.7 ± 15.6","56.1 ± 15.2","0.017"]
["Period of time from EGPA onset to study admission (years), mean ± SD","12.7 ± 8.6","5.9 ± 8.0","0.004"]
[]
[" Laboratory data at diagnosis"]
["  WBC count (/mL), mean ± 1 SD","15270.8 ± 7400.2","16263.0 ± 8029.5","0.64"]
["  Blood eosinophils (/mL), mean ± 1 SD","7585.9 ± 6505.9","6856.2 ± 5609.3","0.67"]
["  MPO-ANCA yes/no (%)","11 / 29 (27.6%)","4 / 16 (20.0%)","0.53"]
["  PR3-ANCA yes/no (%)","2 / 38 (5.0%)","2 / 18 (10.0%)","0.46"]
["  IC > 1.5 mg/mL yes/no (%)","5 / 19 (20.8%)","2 / 10 (16.7%)","0.77"]
["  RF > 15 IU/mL yes/no (%)","17/17 (50.0%)","4/14 (22.2%)","0.10"]
["  BNP > 18.7 pg/mL yes/no (%)","18 / 16 (52.9%)","8 / 11 (42.1%)","0.45"]
["  IgE IU/mL, median (range)","515 (8.7-28403) ✻","779 (43.5-2053) ✻","0.99"]
["  IgG IU/mL, mean ± SD yes/no (%)","1446.4 ± 523.0","1448.7 ± 461.6","0.27"]
[]
["Clinical manifestations at diagnosis, yes/no (%)"]
["  Asthma","40/0 (100.0%)","20/0 (96.4%)","-"]
["  Paranasal sinusitis","38 / 2 (95.0%)","19 / 1 (95.0%)","-"]
["  Eosinophilic otitis media","7 / 33 (17.5%)","3 / 17 (15.0%)","0.81"]
["  Multiple polyneuropathy","40/0 (100.0%)","19 / 1 (95.0%)","0.15"]
["  Minimum MMT score","3.4 ± 1.0","3.7 ± 1.1","0.44"]
["  Pulmonary involvement","21 / 16 (56.8%)","14 / 6 (70.0%)","0.33"]
["  Myocardial involvement","24 / 16 (60.0%)","5 / 15 (25.0%)","0.011"]
["  Gastrointestinal tract involvement","32 / 5 (86.4%)","14 / 5 (73.7%)","0.24"]
["  Liver, gall bladder, pancreas","8 / 29 (21.6%)","2 / 17 (10.5%)","0.30"]
["  Renal involvement","15 / 24 (38.5%)","6 / 14 (30.0%)","0.52"]
["  Skin involvement","29 / 9 (76.3%)","10 / 10 (50.0%)","0.042"]
["  Arthralgia","23 / 16 (59.0%)","11 / 9 (55.0%)","0.077"]
["  Myalgia","9 / 29 (23.7%)","1 / 19 (0.05%)","0.073"]
["  Central nervous system involvement","9 / 31 (22.5%)","7 / 13 (35.0%)","0.30"]
[]
["BVAS"]
["At diagnosis","31.3 ± 8.2","27.3 ± 7.2","0.07"]
["Before treatment-group allocation","16.1 ± 4.1","12.0 ± 3.7","0.0004"]
[]
["ACR1994　(4/5/6)","11 / 15 / 14","1 / 10 / 9","0.12"]
["ACR2022　 (mean ± SD)","12.6 ± 1.9","13.0 ± 1.8","0.47"]
["FFS1998 (0/1/2/3)","16 / 16 / 7 / 1","9 / 8 / 7 / 0","0.98"]
["FFS2009 (0/1/2/3)","14 / 15 / 10 / 1","7 / 10 / 3 / 0","0.88"]
[]
["Initial treatment"]
["  mPSL pulse yes/no (%)","30 / 10 (69.0%)","13 / 7 (73.3%)","0.42"]
["  PSL (mg) (mean ± SD)","44.9 ± 11.5","43.0 ± 9.7","0.53"]
["  Immunosuppressant yes/no (%)","40 / 0 (100.0%)","15 / 5 (75.0%)","0.001"]
["  CYC/AZA/CSA/MTX/RTX","23/7/8/2/0","12/0/2/1/0","0.006"]
["  CYC yes/no (%)","23 / 17 (57.5%)","12 / 3 (80.0%)","0.12"]
[]
["Maintenance treatment before group allocation"]
["  PSL (mg) (mean ± SD)","17.6 ± 11.1","14.3 ± 8.4","0.24"]
["  Immunosuppressant yes/no (%)","40 / 0 (100%)","0/ 20 (0%)","＜0.001"]
["  CYC/AZA/CSA/MTX/RTX","12/9/6/11/2","0/0/0/0/0","＜0.001"]
["  IVIG yes/no (%)","30 / 10 (75.0%)","10 / 10 (50.0%)","0.053"]
[]
["Mepolizumab treatment"]
["Period from EGPA diagnosis to mepolizumab initiation (year), mean ± 1 SD","7.1 ± 7.0","3.4 ± 4.1","0.034"]
["Mepolizumab administration period (months), mean ± 1 SD","47.0 ± 34.3","30.8 ± 24.4","0.06"]
["Period from mepolizumab initiation to induction of remission (months), mean ± 1 SD","11.9 ± 15.1","6.8 ± 9.8","0.028"]
["Mepolizumab (mg) (300 / 100)","40 / 0 (100%)","20 / 0 (100%)","-"]
[]
["Last examination"]
["  PSL (mg) (mean ± SD)","9.4 ± 4.5","7.6 ± 5.1","0.16",{"$nulls":8},"なし"]
["  Immunosuppressant yes/no (%)","30 / 10 (75.0%)","0/ 20 (0%)","＜0.001",{"$nulls":8},10]
["  CYC/AZA/CSA/MTX/RTX","1 / 11 / 6 / 8 / 4","0/0/0/0/0","＜0.001"]
[]
["✻: median (range)"]
[]
["AZA, azathioprine; BVAS, Birmingham Vasculitis Activity Score; CSA, cyclosporine; CYC, cyclophosphamide;  EGPA, eosinophilic granulomatosis with polyangiitis; IC, immune complex; IVIG, intravenous immunoglobulin; MMT, manual muscle test; MPO-ANCA, myeloperoxidase-specific antineutrophil cytoplasmic antibodies; mPSL, methyprednisolone; MTX, methotrexate; PR3, protein 3; PSL, prednisolone;  RTX, rituximab "]